ArticleCureus2025
Takotsubo Cardiomyopathy in a Patient Undergoing 5-Fluorouracil Infusion: Considerations for Folinic Acid, 5-Fluorouracil, and Oxaliplatin (FOLFOX) Cardiotoxicity and Rechallenge.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cancer therapy-associated Takotsubo cardiomyopathy: A narrative review of mechanisms, drug associations, and clinical implications.American heart journal plus : cardiology research and practice · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Takotsubo cardiomyopathy (TCM) is a rare but reversible cause of transient ventricular dysfunction, often triggered by sympathetic stimulation from physical or emotional stress. Patients with a history of TCM undergoing cardiotoxic chemotherapy such as FOLFOX (folinic acid, 5-fluorouracil (5-FU), and oxaliplatin) require vigilant monitoring due to potential cardiac complications, including coronary vasospasm and direct myocardial toxicity. We present a case of progressively worsening TCM diagnosed via coronary angiography and left ventriculography three days after a patient received their first FOLFOX infusion for sigmoid adenocarcinoma. The cardiomyopathy resolved with conservative management, and one month later, the patient was admitted for a monitored FOLFOX rechallenge in the telemetry unit, which she tolerated well. This case highlights the importance of cardiac surveillance in patients with prior TCM requiring chemotherapy and discusses strategies for minimizing cardiotoxic risk during 5-FU rechallenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.